Status:
COMPLETED
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Comprehensive Cancer Network
Conditions:
Brain Cancer
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain meta...
Eligibility Criteria
Inclusion
- All patients age 18 years and older with histologically proven non-small cell lung cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior surgery or radiation is allowed as long as the target metastatic lesion(s) has not been treated with previous radiation.
- Adequate organ function (section 3.1.10).
- ECOG performance status 0-2.
- Life expectancy of \>=12 weeks.
- Systemic chemotherapy washout period \>=7 days.
Exclusion
- Patients who have previously been treated with whole brain irradiation, pediatric patients (age \<18), pregnant women, and patients who are unable to give informed consent.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00946673
Start Date
June 1 2009
End Date
July 1 2015
Last Update
October 6 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305
2
Moffitt Cancer Center
Tampa, Florida, United States, 33612